Author: Newsdesk

ROLLING MEADOWS, Ill., May 08, 2026 (GLOBE NEWSWIRE) — RYTHM, Inc. (Nasdaq: RYM) today announced that Navy Pier has named RYTHM, Chicago’s flagship THC brand, as its official THC beverage partner, bringing hemp-derived THC beverages to the most visited destination in the Midwest, welcoming more than 8 million guests annually. The multi-year partnership launches May 22 and centers on the RYTHM Stage in the Navy Pier Beer Garden, brought to life through events, pop-ups, sampling, and seasonal programming.

Guests will have access to RYTHM’s full beverage lineup, including Sativa and Kush, each designed around distinct, effect-driven experiences. Señorita THC Margaritas will also be available alongside RYTHM at the garden and at select bars and points of sale across the Pier. The lineup of THC beverages arrives just in time for Navy Pier’s largest summer of Pier-produced programming ever. All beverages will be available in 12oz cans with 5mg of hemp-derived THC.

“Consumers are choosing THC, and the venues they love are responding,” said Ben Kovler, Chairman and Interim CEO of RYTHM, Inc. “Navy Pier welcomes millions of visitors every year, and this summer, RYTHM will be part of that experience. As a Chicago-based company leading the industry forward, we are proud to showcase RYTHM and Señorita at our city’s premier leisure and cultural destination. Chicagoans are already embracing our THC beverages at iconic locations across the city, and we are excited for Navy Pier guests to experience them next.”

“As Navy Pier prepares for one of its most exciting seasons yet, we’re proud to partner with RYTHM to bring vibrant new energy to the Navy Pier Beer Garden,” said Elizabeth Halajian, Chief of Advancement at Navy Pier. “Partners like RYTHM help sustain and preserve Navy Pier as a cultural destination while supporting the free public programming and memorable guest experiences that define summers in Chicago.”

Partnering with Navy Pier is the latest milestone in RYTHM, Inc.’s growing presence across the country’s most iconic live entertainment and destination venues. Earlier this year, Señorita and RYTHM made history as the first THC beverages available at a major U.S. arena when Chicago’s United Center named RYTHM, Inc. its official THC sponsor. Both brands are also available across Chicago’s 16″ on Center venues, including The Salt Shed, Thalia Hall, and The Empty Bottle, as well as Jam Productions venues including Riviera Theatre, Park West, and The Vic.

RYTHM and Señorita will be available to purchase at Navy Pier starting May 22. The brands can also be found at over 6,000 locations nationwide and ordered through direct-to-consumer delivery at RYTHMDrinks.com and SenoritaDrinks.com. Follow @RYTHMDrinks and @SenoritaDrinks on Instagram to stay up to date on the latest brand news and summer happenings.

About RYTHM, Inc.

RYTHM, Inc.’s portfolio of THC brands includes the most recognized and trusted names in the cannabis and hemp industries, including RYTHM, incredibles, Dogwalkers, Beboe, Señorita THC Margaritas, &Shine, Doctor Solomon’s, and Good Green. With products available in thousands of physical locations and online, supported by an iconic lineup of brands rooted in quality and safety, RYTHM, Inc. is cementing its position as America’s THC Company. Through a focus on innovation, the Company is continually shaping THC experiences to meet the evolving preferences of consumers across the country. Learn more and explore the full brand portfolio at https://rythminc.com/.

About Navy Pier
Located on Lake Michigan, Navy Pier is the most visited destination in the Midwest, stretching more than six city blocks and welcoming nearly 9 million annual guests. Originally opened in 1916 as a shipping and recreation facility, this Chicago landmark showcases over 50 acres of parks, restaurants, attractions, retail shops, sightseeing and dining cruise boats, exposition facilities, and more. The Pier celebrated its 100th anniversary in 2016 with the unveiling of the Centennial Wheel, Polk Bros Park, and Peoples Energy Welcome Pavilion. Today, Navy Pier continues to usher in its second century with ongoing redevelopment efforts including the 223-room Sable hotel, the all-transient Navy Pier Marina, and thrilling new attractions such as Flyover Chicago. The Pier is proud to present free programming designed to inspire and engage communities across the city and globe, including the #1 Fireworks display in the nation. For more information, visit NavyPier.org.

 Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning RYTHM, Inc. and other matters. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements including, without limitation, statements regarding future financial results including the potential for revenue growth from hemp-derived THC sales, the expansion or continuation of hemp-derived THC Sales, and potential trends in consumer preferences. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “launches” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that the Company believes may affect its business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You should carefully consider the risks and uncertainties that affect the Company’s business, including those described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K filed for the year ended December 31, 2025 with the SEC, which can be obtained on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this communication. Except as required by applicable law, the Company does not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You are advised, however, to consult any further disclosures the Company makes on related subjects in its public announcements and filings with the SEC.

Investor Relations Contact

[email protected]

Media Contact:

[email protected]

ATLANTA, May 08, 2026 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against Graphic Packaging Holding Company (“Graphic Packaging” or the “Company”) (NYSE: GPK). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding Graphic Packaging’s business, operations, and prospects, including allegations that: (i) Graphic Packaging was experiencing significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (ii) Defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company’s business and financial results; (iii) Defendants likewise overstated the strength and sustainability of the Company’s business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; and (iv) accordingly, the Company’s previously issued FY 2025 financial guidance was unreliable and/or unrealistic.

If you purchased Graphic Packaging shares between February 4, 2025 and February 2, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/graphic-packaging-holding-company/ for more information. 

The deadline to ask the court to be appointed lead plaintiff in the case is July 6, 2026. 

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey Holzer, Esq. 
(888) 508-6832 (toll-free)
[email protected]

SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 1,478,873 additional shares, at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, were approximately $805 million. All of the shares of common stock in the offering were sold by Cytokinetics.

Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies acted as joint book-running managers for the offering. Mizuho acted as lead co-manager for the offering and Citizens Capital Markets, Needham & Company, B. Riley Securities and H.C. Wainwright & Co. acted as co-managers for the offering.

The securities described above were offered by Cytokinetics pursuant to a shelf registration statement (including a base prospectus) filed on February 27, 2025 with the Securities and Exchange Commission (SEC), which has become automatically effective. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and can be accessed for free on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2^nd Floor, New York, New York 10014, by telephone at 866-718-1649 or by email at [email protected]; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526 or by email at [email protected]; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at [email protected] and [email protected]; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About
Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO^® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757